$56.65 0.76 (+1.36%)
2/13/2012 1:56 PM

Novartis AG (ADR) (NYSE:NVS)

CAPS Rating: 5 out of 5

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.

Results 1 - 20 of 205 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar RTChokies (94.59) Submitted: 1/16/2012 10:01:04 AM : Outperform Start Price: $56.27 NVS Score: -3.44

fair value is 71

Recs

0
Member Avatar Dan22italy (43.45) Submitted: 12/19/2011 1:00:13 AM : Outperform Start Price: $56.19 NVS Score: -10.14

one of best pharma, good dividend

Recs

0
Member Avatar starbucks4ever (99.03) Submitted: 11/18/2011 2:07:58 AM : Outperform Start Price: $55.17 NVS Score: -7.88

A reasonably safe bet. The management is finished destroying value through acquisitions: the last cash that remained to be squandered has been squandered last year, and during a debt crisis nobody will lend them money for the next purchase. That leaves us with a low PE, and with speculators assuming (mistakenly) that with no more empire building the "E" will finally accrue to them. This illusion will put a floor under the price, especially when the "E" is stable and speculators are desperately looking for stability.

Recs

0
Member Avatar MojoJoe (22.48) Submitted: 9/21/2011 11:34:38 AM : Outperform Start Price: $55.68 NVS Score: -11.33

Excellent company, great dividend analysis.

Recs

0
Member Avatar clayman14 (93.47) Submitted: 9/15/2011 4:30:29 PM : Outperform Start Price: $55.94 NVS Score: -10.39

Swiss Compant + Decent Yield + Pharma

Recs

0
Member Avatar Ikarruss (30.34) Submitted: 9/6/2011 12:58:29 PM : Outperform Start Price: $55.52 NVS Score: -14.99

Good company, makes generics, good ratios, has been delt up with europe, but is not in euro zone

Recs

0
Member Avatar Clint35 (68.01) Submitted: 8/19/2011 1:46:31 AM : Outperform Start Price: $54.70 NVS Score: -16.33

It's yielding 3.60%. Dividend growth has been good over the last 5 years. The P/E is only 13.11.

Recs

0
Member Avatar einzling44 (40.09) Submitted: 8/10/2011 2:40:26 PM : Outperform Start Price: $55.14 NVS Score: -14.34

Great management and an impressive product pipeline.

Recs

0
Member Avatar beadnell (59.71) Submitted: 8/4/2011 6:17:09 AM : Outperform Start Price: $59.07 NVS Score: -12.95

It is a good day to buy European stocks (even cheaper than when I bought it.)

Recs

0
Member Avatar Jamanji (27.03) Submitted: 7/8/2011 10:36:44 AM : Outperform Start Price: $62.30 NVS Score: -10.28

Barrons 7-4-11

Recs

0
Member Avatar utri (< 20) Submitted: 7/1/2011 11:44:37 AM : Outperform Start Price: $60.84 NVS Score: -8.62

Has exposure to both patented and generic medicine.
Good balance sheet.
Should move up after Alcon acquisition is complete.

Recs

0
Member Avatar FuriousGreen (57.12) Submitted: 5/2/2011 2:20:51 PM : Outperform Start Price: $59.28 NVS Score: -3.70

Solid in recession, solid outside of recession.

Recs

0
Member Avatar PsychoDr (86.23) Submitted: 4/22/2011 9:29:00 AM : Outperform Start Price: $57.03 NVS Score: -1.98

One part of my health care triple play. Novartis is a pharmaceutical company with a nice dividend, international reach, and generic drug presence. Generics are the wave of the future and any company that can provide lower price medication for an emerging international market community is a strong long term play. Health care will see significant growth going forward, I want in on all aspects of the industry.

Recs

0
Member Avatar Greenesthorn (44.61) Submitted: 4/16/2011 6:33:54 PM : Outperform Start Price: $54.60 NVS Score: +0.04

Good fundamentals, new FDA approvals

Recs

0
Member Avatar jtothes (93.77) Submitted: 4/14/2011 10:29:13 AM : Outperform Start Price: $55.63 NVS Score: -1.43

Undervalued? Maybe, but with some new FDA approvals there should be ample opportunity for growth

Recs

0
Member Avatar PuroDog (95.64) Submitted: 4/8/2011 2:25:41 PM : Outperform Start Price: $55.39 NVS Score: +0.40

No baggage

Recs

0
Member Avatar healthcarevalue (96.65) Submitted: 3/9/2011 12:55:59 PM : Outperform Start Price: $55.26 NVS Score: +0.26

NVS, Novartis, 119, 418 employees, based in Basel, Switzerland. Debt/equity of 0.36, market cap of 126.26 billion, relatively low price/earnings ratio as compared to others in industry, of 12.95. Diversified interests include vaccines, infectious disease treatment, and specifically, over-the-counter (OTC) drugs, animal health, and vision products.

Recs

0
Member Avatar alienbrett (< 20) Submitted: 2/26/2011 12:29:49 PM : Underperform Start Price: $56.06 NVS Score: +0.84

Novartis is just a tad bit over valued, and soon, it will be realized. But over a long term, it will greatly improve and skyrocket.

Recs

0
Member Avatar Odiseo (< 20) Submitted: 2/24/2011 3:13:23 PM : Outperform Start Price: $56.24 NVS Score: -9.98

Good pipe line, good generic, stable Pharma. We will not stop buying medicine and NVS will not stop selling. At some point they will com put ahead.

Recs

0
Member Avatar KempInTheWoods (65.16) Submitted: 2/10/2011 8:28:49 PM : Outperform Start Price: $53.73 NVS Score: +2.67

Been fence sitting for some time. Seems undervalued for what it is. Well run Swiss healthcare with 60% of sales outside Europe. Wide range of drugs and tools.

Featured Broker Partners


Advertisement